Astrazeneca Pharma India rose 3.7% to Rs 1,400 at 10:25 IST on BSE after the company announced receiving marketing permission for Durvalumab (ImfinziTM) in India.
The announcement was made after market hours yesterday, 21 June 2018.Meanwhile, the S&P BSE Sensex was down 79.64 points, or 0.22% to 35,352.75.
On the BSE, 25,000 shares were traded in the counter so far compared with average daily volumes of 30,000 shares in the past two weeks. The stock had hit a high of Rs 1,420 and a low of Rs 1,381 so far during the day. The stock hit a 52-week high of Rs 1,515.40 on 19 June 2018. The stock hit a 52-week low of Rs 882.55 on 22 August 2017.
AstraZeneca Pharma India announced that it has received Import & Market permission for Durvalumab (ImfinziTM) in India by the Drug Controller General of India (DCGI). The receipt of this permission paves way for the launch of Durvalumab (ImfinziTM) in India.
Durvalumab provides a treatment option for patient with locally advanced, unresectable Non-Small Cell Lung Cancer (NSCLC) and metastatic urothelial carcinoma. Durvalumab is a patented product of AstraZeneca global.
AstraZeneca Pharma India reported net profit of Rs 3.22 crore in Q4 March 2018 as against net loss of Rs 9.56 crore in Q4 March 2017. Net sales rose 30.27% to Rs 150.73 crore in Q4 March 2018 over Q4 March 2017.
AstraZeneca Pharma India is the operating company covering manufacturing, sales and marketing activities. It has an innovative portfolio to address the unmet needs in non-communicable diseases such as diabetes, heart disease, cancer, asthma & COPD.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
